[111In]In-TE-1132

N/A

Report date: 2025/11/14 17:20:12

Base Information

Drug Name[111In]In-TE-1132

Drug Alias Name[111In]In-TE-1132111In-TE-1132

ClassificationRadiation-emitting products > Nuclides > Indium > 111InBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Radiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionCA19.9(Carbohydrate antigen 19-9) inhibitors

TargetsCA19.9(Carbohydrate antigen 19-9)

Therapy Area/IndicationsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryTaiwan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesImmunwork Inc

China Registration ClassN/A

Develop Information

Active CompaniesImmunwork Inc

Inactive CompaniesN/A

Active IndicationsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A